Drug
Emd 521873
Emd 521873: highest development phase Phase 1, developed by Merck. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Merck
Trials
| Drug | Phase | Indication |
|---|---|---|
| EMD 521873 NCT01032681 | Phase 1 | Non-Hodgkin Lymphoma |
Latest
No recent events.
Follow Emd 521873 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.